Microcavity based Biosensor for Detection of SARS-CoV-2.

During a pandemic, infectious diseases can lead to significant health and societal challenges. While advanced technologies have been developed for the accurate detection of SARS-CoV-2, they still have limitations. The entire detection process, including sampling, pre-treatment, analysis, and data reporting, often takes several hours, leading to delays in treatment decisions. Therefore, there is a need for a technique that can provide rapid results, preferably accessible directly to individuals, benefiting both the general public and healthcare systems. In this study, we introduce a biosensor that utilizes microcavity-based dark-field reflectivity, thus providing a powerful technique for sensing the covering virus layer. Moreover, aptamers are used to specific bonding of viruses, leading to improved biosensor accuracy. Data obtained from the microcavity-based biosensor show high sensitivity to the detection of pseudo-viruses, with the limit of detection at 102 copies. In comparison, the polymerase chain reaction requires more than 103 copies for monitoring the viruses. Therefore, the biosensor shows considerable potential for point-of-care testing.